AdvisorShares Psychedelics ETF began trading on the NYSE Arca exchange last September as the first U.S.-listed actively managed ETF to deliver dedicated investment exposure to psychedelic companies joining Horizons Psychedelic Stock Index ETF and 3 tracking (non-trading) indices in that sector. We compare all 5 below to help you decide which ETF to invest in, if any, or which ETF or Index to follow for the latest activity in the fledgling sector.

1. The Advisor Shares Psychedelics ETF (PSIL)

The ETF:

• consists of 27 constituents, namely: Compass Pathways (12.2%); Cybin (9.9%); ATAI (8.2%); FSD Pharna (6.1%); Intracellular Therapies (6.0%); Seelos (5.9%); Bright Minds (5.2%); GH Research (4.9%); Alkermes (4.9%); Greenbrook (4.9%); Mind Medicine (3.8%); Numinus (3.5%); Relmada Therapeutics (3.4%); Small Pharma (2.9%); Reunion Neuroscience (2.4%) and PsyBio (2.1%) with 11 constituents of less than 1% each,
• has regional allocation of Canada (35.4%); USA (35.2%); UK (15.8%); Europe (13.6%),
• trades on the NYSE Arca under the symbol PSIL with a CUSIP number 00768Y362 (Go here for more information on CUSIP),
• has an expense ratio of 0.60%,
• is actively managed and
• has a market capitalization of $7.1M.

2. The Horizons Psychedelic Stock Index ETF (PSYK)

The ETF:

• consists of just 10 constituents, namely: Seelos (13.1%) ATAI (11.4%), GH Resources (10.4%), Compass Pathways (10.3%), Abbvie (8.8%), Johnson & Johnson (8.7%), Numinus (8.1%), Revive Therapeutics (7.9%), Cybin (7.4) and Mind Medicine (3.8%).
• trades on the OTC exchange under the symbol HPSYF with a CUSIP number 44056U104 (Go here for more information on CUSIP),
• has an expense ratio of 0.85%,
• is passively managed and
• has a market capitalization of $15.3M.

3. The Psychedelic Invest Index

The index:

• tracks 59 public psychedelic companies that have a portion of their business focused on psychedelics,
• is passively managed.
• The Index does not trade but its daily performance can be followed here.

4. The Psychedelic Market Leaders Index

The index:

• tracks the 29 largest public psychedelic companies and
• is passively managed.
• The Index does not trade but its daily performance can be followed here.

5. The munKNEE Psychedelic Drug Stocks Index

The index:

• tracks those psychedelic stocks that have market capitalizations in excess of $50M (and Zynerba Pharmaceuticals at less than $50M),
• consists of 8 companies that research the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances (read 10 Psychedelic Substances And The 36 Companies Researching Them), namely: Cybin (CYBN); Seelos Therapeutics (SEEL); Zynerba (ZYNE); ATAI Life Sciences (ATAI); Compass Pathway (CMPS); Mind Medicine (MNMD); Allied (ALID); GH Resources (GHRS),
• is passively managed and
• has a market capitalization of $1.9B.
• The Index does not trade but its performance can be tracked in the weekly articles I write on this sector for TalkMarkets.com (see here).

More By This Author:

Ascend Wellness Q3 Report: Record Revenue, Adjusted Gross Profit And EBITDA Margin
Ayr Wellness Q3 Financial Metrics All Show Major Improvements
Canopy Growth Q2 Financial Report: Loss In Net Income Reduced Dramatically